Malignant melanoma is an antigenic tumor recognized by specific lymphocytes
. Several melanoma-associated antigens have been shown to cause tumor rejec
tion in vitro. Escape from immunosurveillance by melanoma cells is the resu
lt of several mechanisms such as total loss or decreased expression of HLA
antigens, alterations in the expression of tumor-associated antigens or def
iciencies in the antigen-processing machinery. Additional important feature
s include the influence of endogenous and exogenous cytokines such as inter
ferons or interleukins and expression of adhesion molecules or co-stimulato
ry molecules. All these factor have to be considered for the development of
new immunoregulatory treatment modalities against advanced melanoma.